[
  {
    "ts": null,
    "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q1 2025 Update",
    "summary": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q1 2025 Update",
    "url": "https://finnhub.io/api/news?id=e27504393d6270f71f4779aed94b422dee3a3fcabc889d6582ddb2468c20c3d3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747865679,
      "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q1 2025 Update",
      "id": 134631523,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e27504393d6270f71f4779aed94b422dee3a3fcabc889d6582ddb2468c20c3d3"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease",
    "summary": "Eli Lilly and Company (NYSE: LLY) announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (donanemab), an injection for intravenous infusion every four weeks to treat mild cognitive impairment and mild dementia due to Alzheimer's disease in adults who are Apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers. Kisunla is the first amyloid-targeting therapy for people with Alzheimer's registered in Australia and the only amyl",
    "url": "https://finnhub.io/api/news?id=643b0fe6e5724bab0956173937db64a87f25c94fc22657cd71d4bab0ad6894f5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747858860,
      "headline": "Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease",
      "id": 134647907,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (donanemab), an injection for intravenous infusion every four weeks to treat mild cognitive impairment and mild dementia due to Alzheimer's disease in adults who are Apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers. Kisunla is the first amyloid-targeting therapy for people with Alzheimer's registered in Australia and the only amyl",
      "url": "https://finnhub.io/api/news?id=643b0fe6e5724bab0956173937db64a87f25c94fc22657cd71d4bab0ad6894f5"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Alzheimer's Drug Gets Approval in Australia",
    "summary": "By Kelly Cloonan Eli Lilly has received approval in Australia to market its Alzheimer's treatment Kisunla. The pharmaceutical company said Wednesday the Australian Therapeutic Goods...",
    "url": "https://finnhub.io/api/news?id=6af537915f6345f5f9bf5d6fb6609b45fec0a94fb9e451dc81485de3b227285f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747847471,
      "headline": "Eli Lilly's Alzheimer's Drug Gets Approval in Australia",
      "id": 134630272,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "By Kelly Cloonan Eli Lilly has received approval in Australia to market its Alzheimer's treatment Kisunla. The pharmaceutical company said Wednesday the Australian Therapeutic Goods...",
      "url": "https://finnhub.io/api/news?id=6af537915f6345f5f9bf5d6fb6609b45fec0a94fb9e451dc81485de3b227285f"
    }
  },
  {
    "ts": null,
    "headline": "Medtronic to split off its fast-growing diabetes business to unlock its value",
    "summary": "Medtronic to split off its fast-growing diabetes business to unlock its value",
    "url": "https://finnhub.io/api/news?id=f6ce9fa771641076759a70a14c3961982bac4101705989885d82a8324ea29ecf",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747821600,
      "headline": "Medtronic to split off its fast-growing diabetes business to unlock its value",
      "id": 134632782,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Medtronic to split off its fast-growing diabetes business to unlock its value",
      "url": "https://finnhub.io/api/news?id=f6ce9fa771641076759a70a14c3961982bac4101705989885d82a8324ea29ecf"
    }
  },
  {
    "ts": null,
    "headline": "Lilly’s former small molecule head makes the leap to a rising biotech in obesity",
    "summary": "Utpal Singh joined the peptide-focused biotech Zealand Pharma last month after it notched a massive obesity deal with Roche.",
    "url": "https://finnhub.io/api/news?id=5a1e7a414bd87187e9ee7f429acb6faa8370ff48d28e61cfd7b557eb53425ff2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747814400,
      "headline": "Lilly’s former small molecule head makes the leap to a rising biotech in obesity",
      "id": 134628147,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Utpal Singh joined the peptide-focused biotech Zealand Pharma last month after it notched a massive obesity deal with Roche.",
      "url": "https://finnhub.io/api/news?id=5a1e7a414bd87187e9ee7f429acb6faa8370ff48d28e61cfd7b557eb53425ff2"
    }
  }
]